Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Lung cancer and personalized medicine . Advances in Experimental Medicine and Biology; 2016. p. 1–19.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Khaled HM, Mikhail NN, et al. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;437971.
   Google Scholar
• Larbi A. AMAAC workshop, Algiers November, 19, 2011.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Dubey AK, Gupta U, Jain S. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis. Chin J Cancer. 2016;35(1):71.
   PubMedGoogle Scholar
• Butnor KJ, Beasley MB. Resolving dilemmas in lung cancer staging and histologic typing. Arch Pathol Lab Med. 2007;131(7):1014–1015.
   Web of Science ®Google Scholar
• Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non–small cell lung cancers. Clin Cancer Res. 2005;11(3):1167–1173.
   Web of Science ®Google Scholar
• Cufer T, Ovcaricek T, O’Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013;49(6):1216–1225.
   PubMed Web of Science ®Google Scholar
• Abd El-Monaem Mohamed Abd El-Monaem WHE-S, Zekry MSED. Treatment outcome in patients with metastatic non-small cell lung cancer at presentation (Retrospective study) [original article]. Clin Oncol. 2020 January 26;2020:53–60.
   Google Scholar
• Cao Y, Gao H. Prevalence and causes of air pollution and lung cancer in Xuanwei City and Fuyuan County, Yunnan Province, China. Front Med. 2012;6(1):1–4.
   Google Scholar
• de Alencar Vtl, Formiga MN, de Lima Vcc. Inherited lung cancer: a review [Review]. Ecancermedicalscience. 2020;14:1008.
   Web of Science ®Google Scholar
• Fois SS, Paliogiannis P, Zinellu A, et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 2021;22(2):612.
   PubMed Web of Science ®Google Scholar
• Bennett WP, Alavanja MC, Blomeke B, et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst. 1999;91(23):2009–2014.
   Google Scholar
• Is OI, Sohara Y. Genes associated with susceptibility to lung adenocarcinoma among never smokers suggest the mechanism of disease. Anticancer Res. 2014;34(10):5229–5240.
   Web of Science ®Google Scholar
• Lee V, Mok T, Goto Y, et al. Differences between the east and the west in managing advanced-stage non-small cell lung cancer. Clin Oncol. 2019;31(8):560–569.
   Web of Science ®Google Scholar
• Belani C, Goss G, Blumenschein G Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2012;38(3):173–184.
   Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer [Research support, N.I.H., extramural research support, Non-U.S. Gov’t review]. Mol Cancer. 2018 Feb 19; 17(1):58.
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways [Review]. Cancers (Basel). 2017 May 17; 9(5):52.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al., who classification of the pathology and genetics of tumors of the lungThe 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology . 2015;10(9):1243-1260.
   Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162.
   PubMed Web of Science ®Google Scholar
• Benbrahim Z, Antonia T, Mellas N. EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis [Meta-analysis systematic review]. BMC Cancer. 2018 Sep 14; 18(1):891.
   Google Scholar
• Aye PS, McKeage MJ, Tin Tin S, et al. Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Maori and Pacifica in New Zealand. PloS One. 2021;16(5):e0251357.
   Web of Science ®Google Scholar
• Wheeler DA, Wang L. From human genome to cancer genome: the first decade [Review]. Genome Res. 2013 Jul;23(7):1054–1062.
   PubMed Web of Science ®Google Scholar
• Yoon HY, Ryu JS, Sim YS, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study [Multicenter study research support, Non-U.S. Gov’t]. PloS One. 2020 [Jan 26];15(2):e0228925.
   Web of Science ®Google Scholar
• Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136(5):504–509.
   Web of Science ®Google Scholar
• Butterworth S, Cross DA, Finlay MRV, et al. The structure-guided discovery of osimertinib: the first US FDA approved mutant selective inhibitor of EGFR T790M. MedChemComm. 2017;8(5):820–822.
   PubMed Web of Science ®Google Scholar
• Passaro A, Guerini-Rocco E, Pochesci A, et al. Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment. Pharmacol Res. 2017;117:406–415.
   PubMed Web of Science ®Google Scholar
• Ho HL, Kao HL, Yeh YC, et al. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol. 2019 Jun 21 14(1):59.
   PubMedGoogle Scholar
• Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC [Review]. Ann Oncol. 2018 Jan 1 29(suppl_1):i3–i9.
   PubMed Web of Science ®Google Scholar
• Popper HH, Gruber-Mösenbacher U, Pall G, et al. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers memo-Magazine of European Medical Oncology. 2020;13:11–26.
   Web of Science ®Google Scholar
• Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology–Mainland China subset analysis of the PIONEER study. PloS One. 2015;10(11):e0143515.
   Web of Science ®Google Scholar
• Colombino M, Paliogiannis P, Cossu A, et al. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulm Med. 2019 Nov 11 19(1):209.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Tin Tin S, Khwaounjoo P, et al. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand. Intern Med J. 2020;50(6):716–725.
   Web of Science ®Google Scholar
• Chin LP, Soo RA, Soong R, et al. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer [Review]. J Thorac Oncol. 2012 Nov;7(11):1625–1630.
   PubMed Web of Science ®Google Scholar
• Jiang AG, Lu HY. k-RAS mutations in non-small cell lung cancer patients treated with TKIs among smokers and non-smokers: a meta-analysis. Contemp Oncol (Pozn). 2016;20(2):124–129.
   Google Scholar
• Scheffler M, Ihle MA, Hein R, et al. K-ras Mutation Subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways [Research support, Non-U.S. Gov’t]. J Thorac Oncol. 2019 Apr;14(4):606–616.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346.
   PubMed Web of Science ®Google Scholar
• Shafik HE, Al-Shemarri SH, Al-Enezi F, et al. Frequency of epidermal growth factor mutation status and its effect on outcome of patients with adenocarcinoma of the lung. J Cancer Ther. 2014;5(11):1012.
   Google Scholar
• Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib‐treated patients with lung adenocarcinoma. Cancer Sci. 2008;99(2):303–308.
   Web of Science ®Google Scholar
• Zaki MA, Ramadan RA, Mahmoud MI, et al. Nonenriched PCR versus mutant-enriched PCR in detecting selected epidermal growth factor receptor gene mutations among nonsmall-cell lung cancer patients [Comparative study]. Genet Test Mol Biomarkers. 2015 Aug;19(8):444–449.
   Web of Science ®Google Scholar
• Abo-Elkheir OI, Hafez MR. Characteristics, risk factors and histopathological types of bronchogenic carcinoma among cases presented to Chest Department, Al-Zahraa Hospital, Al-Azhar University. Int J Community Med Public Health. 2018;5(4):1281–1290.
   Google Scholar
• Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J clin oncol. 2011;29(21):2866–2874.
   PubMed Web of Science ®Google Scholar
• Murray S, Dahabreh IJ, Linardou H, et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol. 2008;3(8):832–839.
   PubMed Web of Science ®Google Scholar
• Dufort S, Richard MJ, Lantuejoul S, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC [Research Support, Non-U.S. Gov’t]. J Exp Clin Cancer Res. 2011 May 16 30(1):57.
   Google Scholar
• Choi YL, Sun JM, Cho J, et al. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital [Research Support, Non-U.S. Gov’t]. PloS One. 2013;8(2):e56011.
   Web of Science ®Google Scholar
• Kozu Y, Tsuta K, Kohno T, et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma [Research support, Non-U.S. Gov’t]. Lung Cancer. 2011 Jul;73(1):45–50.
   Web of Science ®Google Scholar
• Bartholomew C, Eastlake L, Dunn P, et al. EGFR targeted therapy in lung cancer; an evolving story. Respir Med Case Rep. 2017;20:137–140.
   Web of Science ®Google Scholar
• Wu J-Y, Wu S-G, Yang C-H, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14(15):4877–4882.
   PubMed Web of Science ®Google Scholar
• Wu J-Y, Yu C-J, Chang Y-C, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23–e31.
   PubMed Web of Science ®Google Scholar
• Yeh P, Chen H, Andrews J, et al. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res. 2013;19(7):1894–1901.
   PubMed Web of Science ®Google Scholar
• Massarelli E, Johnson FM, Erickson HS, et al. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013;80(3):235–241.
   PubMed Web of Science ®Google Scholar
• Ye L, Mesbah Ardakani N, Thomas C, et al. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) resistance mutation in pre-treatment non-small cell lung carcinomas harboring activating EGFR mutations and correlation with clinical outcomes. Pathol Oncol Res. 2020 Oct;26(4):2371–2379.
   PubMed Web of Science ®Google Scholar
• Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(S1):S24.
   PubMedGoogle Scholar
• Yun J, Hong MH, Kim S-Y, et al. YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer. Clin Cancer Res. 2019;25(8):2575–2587.
   Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004 [2004 May 20];350(21):2129–2139.
   PubMed Web of Science ®Google Scholar
• Li K, Yang M, Liang N, et al. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: perplexity and solution. Oncol Rep. 2017;37(3):1347–1358.
   Web of Science ®Google Scholar
• Cheng C, Wang R, Li Y, et al. EGFR exon 18 mutations in East Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics and prognosis. Sci Rep. 2015;5(1):13959.
   Google Scholar
• Yun C-H, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11(3):217–227.
   PubMed Web of Science ®Google Scholar
• Kancha RK, Von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15(2):460–467.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment [Review]. Transl Lung Cancer Res. 2019 Jun;8(3):302–316.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169.
   PubMed Web of Science ®Google Scholar
• Hoglund B, Jin J, Li Y, et al. Mutation in the epidermal growth factor receptor kinase domain. Google Patents; 2018.
   Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Nat Acad Sci. 2004;101(36):13306–13311.
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhao J, Ren P, et al. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma. PloS One. 2018;13(11):e0201682.
   Web of Science ®Google Scholar
• Sun P-L, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2):323–330.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Z. EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. Int J Clin Exp Med. 2014;7(8):1967.
   PubMed Web of Science ®Google Scholar